MX2023014466A - Derivados de piridopirimidina útiles como inhibidores de cinasa wee1. - Google Patents
Derivados de piridopirimidina útiles como inhibidores de cinasa wee1.Info
- Publication number
- MX2023014466A MX2023014466A MX2023014466A MX2023014466A MX2023014466A MX 2023014466 A MX2023014466 A MX 2023014466A MX 2023014466 A MX2023014466 A MX 2023014466A MX 2023014466 A MX2023014466 A MX 2023014466A MX 2023014466 A MX2023014466 A MX 2023014466A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- derivatives useful
- wee1 kinase
- pyridopyrimidine derivatives
- compounds
- Prior art date
Links
- 101100102932 Xenopus laevis wee2-b gene Proteins 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000008518 pyridopyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 101150040313 Wee1 gene Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La descripción proporciona compuestos, o sales farmacéuticamente aceptables de estos, y métodos para usar estos compuestos para inhibir la cinasa Wee1 y tratar, por ejemplo, el cáncer en un sujeto. Los compuestos reivindicados incluyen compuestos (I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196744P | 2021-06-04 | 2021-06-04 | |
| PCT/US2022/032203 WO2022256680A1 (en) | 2021-06-04 | 2022-06-03 | Pyridopyrimidine derivatives useful as wee1 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014466A true MX2023014466A (es) | 2024-05-02 |
Family
ID=82321319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014466A MX2023014466A (es) | 2021-06-04 | 2022-06-03 | Derivados de piridopirimidina útiles como inhibidores de cinasa wee1. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240254123A1 (es) |
| EP (1) | EP4347592A1 (es) |
| JP (1) | JP2024522304A (es) |
| KR (1) | KR20240044409A (es) |
| CN (1) | CN117794932A (es) |
| AU (2) | AU2022287033B2 (es) |
| CA (1) | CA3225152A1 (es) |
| IL (1) | IL309037A (es) |
| MX (1) | MX2023014466A (es) |
| WO (1) | WO2022256680A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4489756A1 (en) | 2022-03-07 | 2025-01-15 | Debiopharm International SA | Methods of treating small cell lung cancer |
| TW202519221A (zh) | 2023-09-14 | 2025-05-16 | 瑞士商德彪製藥國際公司 | Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合 |
| CN120189510A (zh) * | 2023-12-21 | 2025-06-24 | 北京哲源科技有限责任公司 | 一种并环化合物的应用 |
| TW202541810A (zh) | 2023-12-22 | 2025-11-01 | 瑞士商德彪製藥國際公司 | 治療實體腫瘤之方法 |
| WO2025186213A1 (en) | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002069904A2 (en) | 2001-03-02 | 2002-09-12 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
| US9718821B2 (en) * | 2012-02-23 | 2017-08-01 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| GB201306610D0 (en) * | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201612095D0 (en) * | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201800378D0 (en) * | 2018-01-10 | 2018-02-21 | Almac Discovery Ltd | Pharmaceutical compounds |
-
2022
- 2022-06-03 JP JP2024518956A patent/JP2024522304A/ja active Pending
- 2022-06-03 MX MX2023014466A patent/MX2023014466A/es unknown
- 2022-06-03 EP EP22735735.7A patent/EP4347592A1/en active Pending
- 2022-06-03 WO PCT/US2022/032203 patent/WO2022256680A1/en not_active Ceased
- 2022-06-03 KR KR1020247000364A patent/KR20240044409A/ko active Pending
- 2022-06-03 CN CN202280054331.6A patent/CN117794932A/zh active Pending
- 2022-06-03 CA CA3225152A patent/CA3225152A1/en active Pending
- 2022-06-03 US US18/565,598 patent/US20240254123A1/en active Pending
- 2022-06-03 AU AU2022287033A patent/AU2022287033B2/en active Active
- 2022-06-03 IL IL309037A patent/IL309037A/en unknown
-
2025
- 2025-06-23 AU AU2025204724A patent/AU2025204724A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024522304A (ja) | 2024-06-13 |
| AU2025204724A1 (en) | 2025-07-10 |
| CN117794932A (zh) | 2024-03-29 |
| IL309037A (en) | 2024-02-01 |
| EP4347592A1 (en) | 2024-04-10 |
| CA3225152A1 (en) | 2022-12-08 |
| WO2022256680A1 (en) | 2022-12-08 |
| KR20240044409A (ko) | 2024-04-04 |
| AU2022287033A1 (en) | 2024-01-18 |
| AU2022287033B2 (en) | 2025-04-17 |
| US20240254123A1 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014466A (es) | Derivados de piridopirimidina útiles como inhibidores de cinasa wee1. | |
| CO2022015638A2 (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
| GEAP202516803A (en) | Bicyclic amines as cdk2 inhibitors | |
| NI201900013A (es) | Inhibidor de piridopirimidinona cdk2/4/6 | |
| ECSP088630A (es) | Derivados de pirimidina utilizados como inhibidores de cinasa pi-3 | |
| CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
| CO2019012571A2 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| CO2019010559A2 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos | |
| UY30297A1 (es) | Inhibidores de la quinasa c-fms-i | |
| MX2025001016A (es) | Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de glutaminil-peptido ciclotransferasa y proteina tipo glutaminil-peptido ciclotransferasa | |
| CO2025003263A2 (es) | Inhibidores de kif18a y usos de estos | |
| MX2019006843A (es) | Inhibidor de cdk4/6. | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| MX2024009943A (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| CO2022010878A2 (es) | Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora a | |
| CO2021001277A2 (es) | Inhibidores de triazol glicolato oxidasa | |
| PE20250667A1 (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2 | |
| AR110540A1 (es) | Inhibidores de incrustaciones sólidas de liberación controlada | |
| CL2025000672A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer. | |
| CL2023001244A1 (es) | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática | |
| CO2024009091A2 (es) | Compuestos heterociclicos como inhibidores de dyrk1a | |
| CO2022000118A2 (es) | Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos | |
| CR11860A (es) | Derivados de dibenzotiazepina y sus usos - 424 |